Reply to Letter to the Editor: Coronary Flow Velocity Reserve Was Impaired in Chronic Hyperhomocysteinemic Patients: Why?
Guang Wang,Liyun He,Tianpei Hong
DOI: https://doi.org/10.1152/ajpendo.00111.2011
2011-01-01
Abstract:Letters to the EditorReply to letter to the editor: coronary flow velocity reserve was impaired in chronic hyperhomocysteinemic patients: why?Guang Wang, Liyun He, and Tianpei HongGuang WangDepartments of Endocrinology and , Liyun HeCardiovascular Medicine, Peking University Third Hospital, Beijing, China, and Tianpei HongDepartments of Endocrinology and Published Online:01 Jun 2011https://doi.org/10.1152/ajpendo.00111.2011MoreSectionsPDF (37 KB)Download PDF ToolsExport citationAdd to favoritesGet permissionsTrack citations to the editor: Hyperhomocysteinemia (HHcy) is considered a potentially modifiable risk factor for coronary artery disease (CAD) and atherosclerosis. The possible mechanisms of accelerated CAD in HHcy include endothelial dysfunction and enhanced oxidative stress (13). However, the precise mechanism by which homocysteine (Hcy) promotes atherosclerosis is not well understood. Hcy could impair coronary microvascular dilated function in healthy individuals. Endothelium-dependent dilation was significantly impaired in acute methionine-induced HHcy patients (1).Noninvasive transthoracic ultrasound imaging of coronary blood flow has been increasingly used to assessment of coronary microcirculation in individuals free of epicardial coronary stenosis (2). Coronary flow velocity reserve (CFVR), which is derived from the ratio of maximal hyperemic to basal coronary blood flow, is an accepted index for assessment of the coronary microcirculation and provides important information about coronary endothelial function. We thank Dr. Kietadisorn et al. (10a) for their interest in our paper (9). We fully agree that CFVR as an independent index of coronary microvascular function has multiple limitations. CFVR is influenced by both epicardial and microvascular factors of the coronary artery. It is also influenced by serious epicardial coronary stenosis, previous myocardial infarction, etc. Pharmacological hyperemic vasodilatation induced by adenosine is a reliable and reproducible technique with which CFVR is evaluated by Doppler echocardiography (3, 10). Adenosine is often used to assess microcirculatory function on the basis of their ability to induce maximal vasodilatation of coronary resistance vessels. This vasodilatation is primarily achieved through effects of adenosine on vascular smooth muscle cells. However, adenosine-induced vasodilatation is partly dependent on the release of nitric oxide (NO) from endothelial cells through the effect of adenosine on endothelial cells and/or via flow-induced shearing force (4, 8). Hence, adenosine-derived CFVR may involve both endothelium-dependent and -independent microcirculatory function. CFVR in response to adenosine may be partly endothelium dependent. In our study, we investigated whether CFVR was damaged in patients with chronic HHcy and, if so, whether this impaired effect was associated with the endothelial dysfunction. Quantification of CFVR was after rest and after adenosine administration by noninvasive Doppler echocardiography. Our results showed that CFVR was significantly lower in the HHcy patients than in the control group (2.76 ± 0.49 vs. 3.09 ± 0.52). In addition, the plasma level of Hcy was negatively correlated with CFVR. Regarding the potential effect of multiple factors on CFVR, the patients with myocardial infarction, CAD (>50% stenosis as shown on angiography), heart failure, renal function impairment, or a serious illness or who were undergoing nitrate or vitamin treatment that would affect their participation were excluded from our study. Consistent with our findings, Coppola et al. (5) showed that the post-methionine CFVR value was reduced significantly both in type 2 diabetic patients and in healthy controls, with the lower value recorded in the diabetic patients. There was a significant inverse relationship between changes in CFVR after the methionine loads and changes in Hcy levels, suggesting impairment of coronary circulation by acute HHcy in type 2 diabetic patients.Tetrahydrobiopterin (BH4) is an essential cofactor for NO synthase (NOS) and is a key regulator of endothelial (e)NOS activity and coupling. Administration of BH4 improves endothelial function in patients with or without CAD (11, 12). In addition, decreased BH4/BH2 ratio, a marker of BH4 oxidation, is also an independent factor of impaired vasorelaxation responses to acetylcholine, suggesting that this factor may exert adverse effects on the endothelial function of the coronary artery. However, it is uncertain whether BH4 or the BH4/BH2 ratio has a more important effect on endothelial function. An association may be present between BH4 levels and the ratio of BH4 to BH2, suggesting that higher values of BH4 are associated with less BH4 oxidation. Hence, vascular endothelial function may be associated not only with increased BH4 levels but also with an increased BH4/BH2 ratio. In 22 hypercholesterolemic patients, BH4 plasma levels were significantly increased by oral supplementation. NO-mediated vasodilatation to acetylcholine was restored by BH4 treatment, suggesting that endothelial dysfunction could be reversed by treatment with BH4 (6). Ueda et al. (15) showed that endothelium function was significantly improved after BH4 supplementation in parallel with elevated plasma BH4 levels in long-term smokers. These studies suggest that increased plasma levels of BH4 alone may exert an important effect for maintaining endothelial function in vivo and may provide a potential approach to preventing CAD.HHcy was associated with impaired vascular endothelial function. Topal et al. (14) reported that the inhibition of NO release induced by Hcy was dependent on eNOS uncoupling due to reduced BH4 availability. Our study demonstrated that CFVR and plasma levels of BH4 were significantly lower in patients with HHcy than in controls. We also observed that Hcy enhanced the activity of NADPH oxidase in human monocytes. Monocyte chemoattractant protein-1 secretion from monocytes was significantly enhanced in response to lipopolysaccharide in patients with HHcy (16). Hcy-induced reactive oxygen species accelerated the development of atherosclerosis in HHcy apoE-/- mice (7). Taken together, HHcy may exert adverse effects on CAD by inducing endothelial dysfunction and oxidative stress. Furthermore, CFVR values were decreased by HHcy, which suggests that HHcy may contribute to this impairment, at least in part, by inducing endothelial dysfunction and oxidative stress mechanisms in patients with chronic HHcy.DISCLOSURESNo conflicts of interest, financial or otherwise, are declared by the author(s).REFERENCES1. Antoniades C , Tousoulis D , Marinou K , Vasiliadou C , Tentolouris C , Bouras G , Pitsavos C , Stefanadis C. Asymmetrical dimethylarginine regulates endothelial function in methionine-induced but not in chronic homocystinemia in humans: effect of oxidative stress and proinflammatory cytokines. Am J Clin Nutr 84: 781–788, 2006.Crossref | PubMed | ISI | Google Scholar2. Bartel T , Yang Y , Muller S , Wenzel RR , Baumgart D , Philipp T , Erbel R. Noninvasive assessment of microvascular function in arterial hypertension by transthoracic Doppler harmonic echocardiography. J Am Coll Cardiol 39: 2012–2018, 2002.Crossref | PubMed | ISI | Google Scholar3. Caiati C , Montaldo C , Zedda N , Bina A , Iliceto S. New noninvasive method for coronary flow reserve assessment: contrast-enhanced transthoracic second harmonic echo Doppler. Circulation 99: 771–778, 1999.Crossref | PubMed | ISI | Google Scholar4. Campisi R , Di Carli MF. Assessment of coronary flow reserve and microcirculation: a clinical perspective. J Nucl Cardiol 11: 3–11, 2004.Crossref | PubMed | ISI | Google Scholar5. Coppola A , Astarita C , Oliviero M , Fontana D , Picardi G , Esposito K , Marfella R , Coppola L , Giugliano D. Impairment of coronary circulation by acute hyperhomocysteinemia in type 2 diabetic patients. Diabetes Care 27: 2055–2056, 2004.Crossref | PubMed | ISI | Google Scholar6. Cosentino F , Hurlimann D , Delli Gatti C , Chenevard R , Blau N , Alp NJ , Channon KM , Eto M , Lerch P , Enseleit F , Ruschitzka F , Volpe M , Luscher TF , Noll G. Chronic treatment with tetrahydrobiopterin reverses endothelial dysfunction and oxidative stress in hypercholesterolaemia. Heart 94: 487–492, 2008.Crossref | PubMed | ISI | Google Scholar7. Dai J , Li W , Chang L , Zhang Z , Tang C , Wang N , Zhu Y , Wang X. Role of redox factor-1 in hyperhomocysteinemia-accelerated atherosclerosis. Free Radic Biol Med 41: 1566–1577, 2006.Crossref | PubMed | ISI | Google Scholar8. Farouque HM , Meredith IT. The assessment of endothelial function in humans. Coron Artery Dis 12: 445–454, 2001.Crossref | PubMed | ISI | Google Scholar9. He L , Zeng H , Li F , Feng J , Liu S , Liu J , Yu J , Mao J , Hong T , Chen AF , Wang X , Wang G. Homocysteine impairs coronary artery endothelial function by inhibiting tetrahydrobiopterin in patients with hyperhomocysteinemia. Am J Physiol Endocrinol Metab 299: E1061–E1065, 2010.Link | ISI | Google Scholar10. Hozumi T , Yoshida K , Ogata Y , Akasaka T , Asami Y , Takagi T , Morioka S. Noninvasive assessment of significant left anterior descending coronary artery stenosis by coronary flow velocity reserve with transthoracic color Doppler echocardiography. Circulation 97: 1557–1562, 1998.Crossref | PubMed | ISI | Google Scholar10a. Kietadisorn R , Kietselaer BL , Schmidt HH , Moens AL. Role of tetrahydrobiopterin (BH4) in hyperhomocysteinemia-induced endothelial dysfuction: new indication for this orphan-drug? Am J Physiol Endocrinol Metab. doi: 10.1152/ajpendo.00084.2011.ISI | Google Scholar11. Maier W , Cosentino F , Lutolf RB , Fleisch M , Seiler C , Hess OM , Meier B , Luscher TF. Tetrahydrobiopterin improves endothelial function in patients with coronary artery disease. J Cardiovasc Pharmacol 35: 173–178, 2000.Crossref | PubMed | ISI | Google Scholar12. Setoguchi S , Mohri M , Shimokawa H , Takeshita A. Tetrahydrobiopterin improves endothelial dysfunction in coronary microcirculation in patients without epicardial coronary artery disease. J Am Coll Cardiol 38: 493–498, 2001.Crossref | PubMed | ISI | Google Scholar13. Tawakol A , Omland T , Gerhard M , Wu JT , Creager MA. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 95: 1119–1121, 1997.Crossref | PubMed | ISI | Google Scholar14. Topal G , Brunet A , Millanvoye E , Boucher JL , Rendu F , Devynck MA , David-Dufilho M. Homocysteine induces oxidative stress by uncoupling of NO synthase activity through reduction of tetrahydrobiopterin. Free Radic Biol Med 36: 1532–1541, 2004.Crossref | PubMed | ISI | Google Scholar15. Ueda S , Matsuoka H , Miyazaki H , Usui M , Okuda S , Imaizumi T. Tetrahydrobiopterin restores endothelial function in long-term smokers. J Am Coll Cardiol 35: 71–75, 2000.Crossref | PubMed | ISI | Google Scholar16. Wang G , Dai J , Mao J , Zeng X , Yang X , Wang X. Folic acid reverses hyper-responsiveness of LPS-induced chemokine secretion from monocytes in patients with hyperhomocysteinemia. Atherosclerosis 179: 395–402, 2005.Crossref | PubMed | ISI | Google ScholarAUTHOR NOTESAddress for reprint requests and other correspondence: G. Wang, Dept. of Endocrinology, Peking University Third Hospital, Peking University Health Science Center, Beijing 100191, China (e-mail: [email protected]com.cn). Download PDF Previous Back to Top FiguresReferencesRelatedInformation Cited ByCorrelation between arterial stiffness and coronary flow velocity reserve in subjects with pulse wave velocity >1400 cm/s11 September 2015 | Clinical and Experimental Hypertension, Vol. 38, No. 1 More from this issue > Volume 300Issue 6June 2011Pages E1177-E1178 Copyright & PermissionsCopyright © 2011 the American Physiological Societyhttps://doi.org/10.1152/ajpendo.00111.2011History Received 7 March 2011 Accepted 9 March 2011 Published online 1 June 2011 Published in print 1 June 2011 Metrics